Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 3-5 October 2012.

abstract：:HMGB1 is a high mobility group protein that can act either as a DNA binding protein or extracellularly as a cytokine-like danger signal. Extracellular HMGB1, either actively secreted or passively released by necrotic cells, is linked to inflammation and cancer. Herein, the results of a study to quantify the expression...

journal_title：Leukemia & lymphoma

authors： Meyer A,Staratschek-Jox A,Springwald A,Wenk H,Wolf J,Wickenhauser C,Bullerdiek J

更新日期：2008-06-01 00:00:00

abstract：:In chronic lymphocytic leukemia (CLL), strategies to overcome drug resistance due to p53 dysfunction are highly needed. Platinum-based compounds such as cisplatinum (CDDP) are active in fludarabine-refractory CLL through a largely unknown mechanism. We analyzed the mechanism of action of CDDP in the context of p53 dys...

journal_title：Leukemia & lymphoma

authors： Tonino SH,Mulkens CE,van Laar J,Derks IA,Suo G,Croon-de Boer F,van Oers MH,Eldering E,Wang JY,Kater AP

更新日期：2015-01-01 00:00:00

abstract：:CD95 is a cell-surface receptor that mediates apoptosis. A possible association between CD95 mutations and extranodal diffuse large B-cell lymphomas (DLBCL) has been reported. To further elucidate this question, a mutation analysis within the 5' region and exon 9 of CD95 was performed in a series of 66 DLBCL patients,...

journal_title：Leukemia & lymphoma

authors： Scholl V,Stefanoff CG,Hassan R,Spector N,Renault IZ

更新日期：2007-05-01 00:00:00

abstract：:The modern treatment of acute myelogenous leukemia (AML), consists of a polychemotherapeutic induction treatment followed by a post-remission therapy of variable intensity and duration and acute promyelocytic leukemia (APL) does not differ from this behavior. However, differently from the other AML subtypes, APL shows...

journal_title：Leukemia & lymphoma

authors： Avvisati G,Petti MC,Mandelli F

更新日期：1993-01-01 00:00:00

abstract：:In this prospective, multicenter, non-randomized study for patients with stage I-II Hodgkin lymphoma, group 1 (without risk-factors [RF]) had three cycles of ABVD chemotherapy (adriamycin, bleomycin, vinblastine, and dacarbazine) and group 2 (any of bulk, extranodal site, >3 regions, raised erythrocyte sedimentation r...

journal_title：Leukemia & lymphoma

authors： Wirth A,Grigg A,Wolf M,Goldstein D,Johnson C,Davis S,Dutu G,Kypreos P,Smith C,Kneebone A,Herzberg M,Joseph D,Catalano J,Roos D,Stone J,Reynolds J

更新日期：2011-05-01 00:00:00

abstract：:Multiple myeloma (MM) is the top indication for high-dose chemotherapy (HDC) with autologous stem cell transplantation (SCT), a strategy which improves progression-free survival and potentially overall survival (OS). Novel induction regimens incorporating the immunomodulatory (IMID) agents, such as thalidomide and len...

journal_title：Leukemia & lymphoma

authors： Benson DM Jr,Panzner K,Hamadani M,Hofmeister CC,Bakan CE,Smith MK,Elder P,Krugh D,O'Donnell L,Devine SM

更新日期：2010-02-01 00:00:00

abstract：:Vasculitis may accompany neoplasias and be of paraneoplastic type or associated with drugs used in patient treatment. We evaluated skin biopsies of twenty-eight cases with vasculitis accompanying leukemias reviewed and clinical outcome was evaluated. Eleven of the 28 cases had paraneoplastic vasculitis and 17 had vasc...

journal_title：Leukemia & lymphoma

authors： Paydaş S,Zorludemir S,Sahin B

更新日期：2000-12-01 00:00:00

abstract：:High-dose melphalan (HDM) followed by autologous hematopoietic cell transplantation (auto-HCT) remains the standard-of-care therapy for multiple myeloma (MM) even with the availability of proteasome inhibitors and immunomodulatory drugs. Gastrointestinal (GI) toxicity is the main cause of morbidity after HDM. Amifosti...

journal_title：Leukemia & lymphoma

authors： Malek E,Gupta V,Creger R,Caimi P,Vatsayan A,Covut F,Bashir Q,Champlin R,Delgado R,Rondon G,Cooper B,de Lima M,Lazarus HM,Qazilbash M

更新日期：2018-08-01 00:00:00

abstract：:The hypomethylating agents azacitidine and decitabine are standard therapy for myelodysplastic syndromes (MDS), and are often used to treat patients with acute myeloid leukemia (AML) unlikely to benefit from cytotoxic chemotherapy. Switching hypomethylating agents after treatment failure is common, but this approach i...

journal_title：Leukemia & lymphoma

authors： Duong VH,Bhatnagar B,Zandberg DP,Vannorsdall EJ,Tidwell ML,Chen Q,Baer MR

更新日期：2015-06-01 00:00:00

abstract：:This retrospective study concerns non-bacterial infections in Asian patients receiving alemtuzumab. The clinical data of 182 patients treated with alemtuzumab alone or alemtuzumab-containing chemotherapy between the years 2003 and 2009 was collected from six Asian countries. Alemtuzumab was used in the setting of fron...

journal_title：Leukemia & lymphoma

authors： Kim SJ,Moon JH,Kim H,Kim JS,Hwang YY,Intragumtornchai T,Issaragrisil S,Kwak JY,Lee JJ,Won JH,Reksodiputro AH,Lim ST,Cheng AL,Kim WS,Kwong YL

更新日期：2012-08-01 00:00:00

abstract：:Neutropenia is known as a clinical consequence in various genetic disorders and other neutropenia-inducing mutations (NIM) nonmalignant diseases. Leukemia development is now a major concern about the mortality of patients with congenital neutropenia. We searched the PubMed database and Google Scholar engine using Engl...

journal_title：Leukemia & lymphoma

authors： Shahrabi S,Maleknia M,Tavakolifar Y,D Zayeri Z,Saki N

更新日期：2019-12-01 00:00:00

abstract：:We investigated the possibility of immunotherapy for multiple myeloma (MM) using myeloma-specific cytotoxic T lymphocytes (CTLs) that were stimulated in vitro by dendritic cells (DCs) pulsing with purified and optimized myeloma lysates. CD14(+) cells were cultured in the presence of GM-CSF and IL-4. On day 6, the imma...

journal_title：Leukemia & lymphoma

authors： Lee JJ,Choi BH,Kang HK,Park MS,Park JS,Kim SK,Pham TN,Cho D,Nam JH,Kim YJ,Rhee JH,Yang DH,Kim YK,Kim HJ,Chung IJ

更新日期：2007-10-01 00:00:00

abstract：:The cytokine IL-6 has been proposed as an autocrine growth factor in multiple myeloma, and is also required for stimulation of immunoglobulin production and secretion in normal plasma cells and myeloma cells. In this study, we showed that secreted IL-6 is detectable by Western blot analysis in a panel of lymphoid and ...

journal_title：Leukemia & lymphoma

authors： Shiao RT,McLeskey SB,Khera SY,Wolfson A,Freter CE

更新日期：1996-04-01 00:00:00

abstract：:Genistein is one of the major isoflavones in soy products. It has been reported that genistein has apoptotic effects on certain hematological malignancies. However, so far there have been no completely comparative studies of the effect of genistein on malignant hematological diseases, especially multiple myeloma. We i...

journal_title：Leukemia & lymphoma

authors： Li W,Frame LT,Hoo KA,Li Y,D'Cunha N,Cobos E

更新日期：2011-12-01 00:00:00

abstract：:Gain-of-function EZH2 mutation promotes H3K27 trimethylation (H3K27me3) and lymphoid transformation of germinal center (GC) derived B-cell lymphoma, such as GCB diffuse large B-cell lymphoma (DLBCL), but not activated B-cell (ABC) DLBCL. It is unclear whether expression levels of EZH2 and consequential H3K27me3 vary b...

journal_title：Leukemia & lymphoma

authors： Zhou Z,Gao J,Popovic R,Wolniak K,Parimi V,Winter JN,Licht JD,Chen YH

更新日期：2015-01-01 00:00:00

abstract：:We have recently shown that the lysosomotropic amine, chloroquine, can inhibit the development of graft-versus-host disease (GVHD) secondary to minor histocompatibility (MiHC) differences in mice. In addition, we have shown that both chloroquine and hydroxychloroquine can inhibit T cell responses in vitro to minor and...

journal_title：Leukemia & lymphoma

authors： Schultz KR,Gilman AL

更新日期：1997-01-01 00:00:00

abstract：:The interaction between neoplastic as well as normal T cells and vascular endothelial cells which is mediated by adhesion molecules play a key role in their trafficking, localization and infiltration. This brief article reviews our studies on the expression of adhesion molecules on leukemic cells isolated from patient...

journal_title：Leukemia & lymphoma

authors： Uchiyama T,Ishikawa T,Imura A

更新日期：1995-02-01 00:00:00

abstract：:Relative risks of treatment-emergent adverse events (TEAEs) and related hospitalization is most accurate when accounting for treatment exposure. AZA-AML-001 showed azacitidine (AZA) prolonged overall survival versus conventional care regimens (CCR) in older patients (≥65 years) with acute myeloid leukemia (AML) by 3.9...

journal_title：Leukemia & lymphoma

authors： Seymour JF,Döhner H,Minden MD,Stone R,Gambini D,Dougherty D,Beach CL,Weaver J,Dombret H

更新日期：2017-06-01 00:00:00

abstract：:We have analyzed the co-expression of the bcr-abl and HoxA9 genes in the follow-up of patients with chronic myeloid leukemia (CML). In the present work we measured the HoxA9 and bcr-abl gene expression in sequential samples. In all patients, bcr-abl and HoxA9 were expressed at detectable levels in every sample. When t...

journal_title：Leukemia & lymphoma

authors： Tedeschi FA,Cardozo MA,Valentini R,Zalazar FE

更新日期：2010-05-01 00:00:00

abstract：:The long-term results of postremission chemotherapy for 122 consecutive, unselected adults (15-65 years) with acute myeloid leukemia (AML) were assessed in two sequential prospective studies involving an identical 3/7-type induction regimen, and in those achieving remission, another course for early consolidation usin...

journal_title：Leukemia & lymphoma

authors： Jehn U

更新日期：1994-09-01 00:00:00

abstract：:There are limited data regarding the role of (18)F-fluorodeoxyglucose positron emission tomography with computed tomography (FDG PET-CT) scanning in primary mediastinal B-cell lymphoma (PMBL). We analyzed 28 patients with PMBL treated with chemotherapy, of whom 25 (89%) also received rituximab and 17 (61%) radiotherap...

journal_title：Leukemia & lymphoma

authors： Cheah CY,Hofman MS,Seymour JF,Ritchie DS,Dickinson M,Wirth A,Prince HM,Wolf M,Januszcewicz EH,Carney DA,Herbert KE,Harrison SJ,Burbury KL,Tam CS

更新日期：2015-01-01 00:00:00

abstract：:In developed nations, Hodgkin lymphoma (HL) is rare in <5-year olds and represent a minority in developing countries. Little is reported about the biology and behavior of these very young patients compared with older children. 18.75% of our pediatric HL patients (0 - 14 years) were <5 years at diagnosis. This group ha...

journal_title：Leukemia & lymphoma

authors： Belgaumi A,Al-Kofide A,Joseph N,Jamil-Malik R,Khafaga Y,Sabbah R

更新日期：2008-05-01 00:00:00

abstract：:Differential gene expression analysis by suppression subtractive hybridization with correlation to the metabolic pathways involved in chronic myeloid leukemia (CML) may provide a new insight into the pathogenesis of CML. Among the overexpressed genes found in CML at diagnosis are SEPT5, RUNX1, MIER1, KPNA6 and FLT3, w...

journal_title：Leukemia & lymphoma

authors： Mascarenhas Cdo C,Ferreira da Cunha A,Brugnerotto AF,Gambero S,de Almeida MH,Carazzolle MF,Pagnano KB,Traina F,Costa FF,de Souza CA

更新日期：2014-08-01 00:00:00

abstract：:High dose chemotherapy with autologous stem cell transplantation (ASCT) improves outcomes in patients 65 years of age or less with multiple myeloma. Survival and costs in a cohort of 16 patients who received melphalan and prednisone as part of a clinical trial were compared with those of 36 patients referred to our ce...

journal_title：Leukemia & lymphoma

authors： Kouroukis CT,O'Brien BJ,Benger A,Marcellus D,Foley R,Garner J,Ingram C,Haines P,Henderson-O'Connor N,Meyer R

更新日期：2003-01-01 00:00:00

abstract：:The association of myeloproliferative and lymphoproliferative disorders is well known after cytotoxic drug or radiation exposure, while it is remarkably rare prior to therapy. We report on a patient simultaneously diagnosed as having polycythemia vera and II3A follicle center cell non-Hodgkin lymphoma (grade 1). At th...

journal_title：Leukemia & lymphoma

authors： Rizzi R,Liso A,Pannunzio A,Carluccio P,Specchia G,Liso V

更新日期：2002-11-01 00:00:00

abstract：:Clinical observation and laboratory evidence suggest that immune mechanisms play an important role in the natural control of evolution of the Ph+ clone in chronic phase as well as during progression of chronic myelogenous leukemia (CML). The understanding of these mechanisms could facilitate development of innovative ...

journal_title：Leukemia & lymphoma

authors： Selleri C,Maciejewski JP

更新日期：2000-04-01 00:00:00

abstract：:This open-label, phase 1 study evaluated the effects of ofatumumab on QTc intervals, safety, efficacy, B-cell and neutrophil counts, complement levels, and cytokine and chemokine concentrations. Fourteen patients with fludarabine-refractory chronic lymphocytic leukemia received 12 ofatumumab infusions. A higher maximu...

journal_title：Leukemia & lymphoma

authors： Patton WN,Lindeman R,Butler AC,Kipps TJ,Jewell RC,Laubscher KH,Zhou YY,Lewis E,Sedoti D,Witman P,Fang L,Chan G

更新日期：2015-01-01 00:00:00

abstract：:The V617F mutation of the JAK2 tyrosine kinase is found in a majority of patients with myeloproliferative disorders. Flow cytometry assays for quantitation of phosphorylated and total protein for JAK2, STAT5, and heat shock proteins (HSPs) were developed to facilitate the study of the JAK/STAT pathway. A cell line hom...

journal_title：Leukemia & lymphoma

authors： Bareng J,Jilani I,Gorre M,Kantarjian H,Giles F,Hannah A,Albitar M

更新日期：2007-11-01 00:00:00

abstract：:The highly controlled degradation of proteins via the ubiquitin-proteasome pathway represents a key mechanism for cell regulation and homeostasis. Ubiquitin-dependent proteolysis, carried out in large part by the E3 ubiquitin ligases, is a critical mode of post-translational modification that is important in regulatio...

journal_title：Leukemia & lymphoma

authors： Lim MS,Elenitoba-Johnson KS

更新日期：2004-07-01 00:00:00

abstract：:The outcomes of acute promyelocytic leukemia (APL) in pregnancy are largely unknown. The MEDLINE database was systematically searched to obtain 43 articles with 71 patients with new-onset APL during pregnancy. Induction therapy included various regimens of all-trans retinoic acid (ATRA), cytarabine, and anthracycline ...

journal_title：Leukemia & lymphoma

authors： Verma V,Giri S,Manandhar S,Pathak R,Bhatt VR

更新日期：2016-01-01 00:00:00